Contribution to more patient-friendly art treatment: Efficacy of continuous low-dose GnRH agonist as the only luteal support - Results of a prospective, randomized, comparative study

International Journal of Endocrinology

Volumn 2015, Issue , 2015, Pages

  Pirard, Céline ^a   Loumaye, Ernest ^b   Laurent, Pascale ^a   Wyns, Christine ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Senior Dir NCD and Phase Rfis1   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BUSERELIN; CHORIONIC GONADOTROPIN; DYDROGESTERONE; ESTRADIOL; ESTRADIOL VALERATE; GANIRELIX; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; PLACEBO; PROGESTERONE; RECOMBINANT CHORIONIC GONADOTROPIN; TRIPTORELIN;

ADULT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EMBRYO TRANSFER; ENDOMETRIAL THICKNESS; EVENING DOSAGE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LOW DRUG DOSE; LUTEAL PHASE; MAJOR CLINICAL STUDY; MENOPAUSE; MENSTRUAL CYCLE; NIDATION; OOCYTE RETRIEVAL; OVARY FOLLICLE MATURATION; OVARY HYPERSTIMULATION; PILOT STUDY; PREECLAMPSIA; PREGNANCY RATE; PREGNANCY TERMINATION; PREGNANCY TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SPINAL DYSRAPHISM; SPONTANEOUS ABORTION; UNSPECIFIED SIDE EFFECT;

EID: 84928485405     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2015/727569     Document Type: Article

References (57)

1. N. S. Macklon and B. C. Fauser, "Impact of ovarian hyperstimulation on the luteal phase, " Journal of reproduction and fertility. Supplement, vol. 55, pp. 101-108, 2000.
2. E. A. Pritts and A. K. Atwood, "Luteal phase support in infertility treatment: a meta-analysis of the randomized trials, " Human Reproduction, vol. 17, no. 9, pp. 2287-2299, 2002.
3. J. Smitz, M. Camus, P. Devroey, N. Bollen, H. Tournaye, and A. C. van Steirteghem, "The influence of inadvertent intranasal buserelin administration in early pregnancy, " Human Reproduction, vol. 6, no. 2, pp. 290-293, 1991.
4. M. van der Linden, K. Buckingham, C. Farquhar, J. A. Kremer, and M. Metwally, "Luteal phase support for assisted reproduction cycles, " Cochrane Database of Systematic Reviews, no. 10, Article ID CD009154, 2011.
5. S. Fujii, S. Sato, A. Fukui, H. Kimura, G. Kasai, and Y. Saito, "Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF, " Human Reproduction, vol. 16, no. 8, pp. 1671-1675, 2001.
6. J. Tesarik, A. Hazout, and C. Mendoza, "Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation, " Human Reproduction, vol. 19, no. 5, pp. 1176-1180, 2004.
7. J. Tesarik, A. Hazout, R. Mendoza-Tesarik, N. Mendoza, and C. Mendoza, "Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist-and antagonist-treated ovarian stimulation cycles, " Human Reproduction, vol. 21, no. 10, pp. 2572-2579, 2006.
8. C. B. Lambalk and R. Homburg, "GnRH agonist for luteal support in IVF? Setting the balance between enthusiasm and caution, " Human Reproduction, vol. 21, no. 10, pp. 2580-2582, 2006.
9. H. Qublah, Z. Amarin, M. Al-Quda et al., "Luteal phase support with GnRH-a improves implantation and pregnancy rates in IVF cycles with endometriumof ?7mmondayof egg retrieval, " Human Fertility (Camb), vol. 11, no. 1, pp. 43-47, 2008.
10. D. F. Razieh, A. R. Maryam, and T. Nasim, "Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection, " Taiwanese Journal of Obstetrics and Gynecology, vol. 48, no. 3, pp. 245-248, 2009.
11. A. Z. Isik, G. S. Caglar, E. Sozen et al., "Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study, " Reproductive BioMedicine Online, vol. 19, no. 4, pp. 472-477, 2009.
12. D. B. Inamdar and A. Majumdar, "Evaluation of the impact of gonadotropin-releasing hormone agonist as an adjuvant in luteal-phase support on IVF outcome, " Journal of Human Reproductive Sciences, vol. 5, no. 3, pp. 279-284, 2012.
13. H. F. Kung, M. J. Chen, H. F. Guua et al., "Luteal phase support with decapeptyl improves pregnancy outcomes in intracytoplasmic sperm injection with higher basal folliclestimulating hormone or lower mature oocytes, " Journal of the Chinese Medical Association, vol. 77, no. 10, pp. 524-530, 2014.
14. G. A. Yildiz, Y. E. Şükür, C. Ateş, and R. Aytaç, "The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial, " European Journal of Obstetrics and Gynecology and Reproductive Biology, vol. 182, pp. 66-70, 2014.
15. C. Pirard, J. Donnez, and E. Loumaye, "GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study, " Human Reproduction, vol. 21, no. 7, pp. 1894-1900, 2006.
16. B. Ata, K. Yakin, B. Balaban, and B. Urman, "GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the longGnRH agonist protocol: a randomized, controlled double blind study, " Human Reproduction, vol. 23, no. 3, pp. 668-673, 2008.
17. B. Ata and B. Urman, "Single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles: is the effect dependent on the type of GnRH analogue used for pituitary suppression?" Reproductive BioMedicine Online, vol. 20, no. 1, pp. 165-166, 2010.
18. JN. Hugues, I. Cedrin-Durnerin, B. Bsandig et al., "Administration of gonadotropin-releasing hormone agonist during the luteal phase of GnRH-antagonist IVF cycles, " Human Reproduction, vol. 21, article i3, 2006.
19. M. Isikoglu, K. Ozgur, and S. Oehninger, "Extension of GnRH agonist through the luteal phase to improve the outcome of intracytoplasmic sperm injection, " Journal of Reproductive Medicine for the Obstetrician and Gynecologist, vol. 52, no. 7, pp. 639-644, 2007.
20. S. S. Yen and R. B. Jaffe, Eds., Reproductive Endocrinology, WB Saunders, Philadelphia, Pa, USA, 1991.
21. A. Tavaniotou, C. Albano, J. Smitz, and P. Devroey, "Impact of ovarian stimulation on corpus luteum function and embryonic implantation, " Journal of Reproductive Immunology, vol. 55, no. 1-2, pp. 123-130, 2002.
22. A. Tavaniotou, C. Albano, J. Smitz, and P. Devroey, "Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist, " Fertility and Sterility, vol. 77, no. 4, pp. 733-737, 2002.
23. N. G. M. Beckers, N. S. Macklon, M. J. Eijkemans et al., "Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulationwith recombinant follicle-stimulating hormone and gnrh antagonist cotreatment, " The Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 9, pp. 4186-4192, 2003.
24. C. Albano, J. Smitz, H. Tournaye, H. Riethmüller-Winzen, A. Van Steirteghem, and P. Devroey, "Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles, " Human Reproduction, vol. 14, no. 6, pp. 1426-1430, 1999.
25. J. Smitz, C. Bourgain, L. van Waesberghe, M. Camus, P. Devroey, and A. C. van Steirteghem, "Aprospective randomized study on oestradiol valerate supplementation in addition to intravaginal micronized progesterone in buserelin and HMG induced superovulation, " Human Reproduction, vol. 8, no. 1, pp. 40-45, 1993.
26. P. Humaidan, H. E. Bredkj'r, L. G. Westergaard, and C. Y. Andersen, "1, 500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study, " Fertility and Sterility, vol. 93, no. 3, pp. 847-854, 2010.
27. J. C. Castillo, M. Dolz, E. Bienvenido, L. Abad, E. M. Casan, and F. Bonilla-Musoles, "Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support, " Reproductive BioMedicine Online, vol. 20, no. 2, pp. 175-181, 2010.
28. B. Radesic and K. Tremellen, "Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates, " Human Reproduction, vol. 26, no. 12, pp. 3437-3442, 2011.
29. S. Kol, P. Humaidan, and J. Itskovitz-Eldor, "GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study, " Human Reproduction, vol. 26, no. 10, pp. 2874-2877, 2011.
30. S. Iliodromiti, V. T. N. Lan, H. M. Tuong, P. H. Tuan, P. Humaidan, and S. M. Nelson, "Impact of GnRH agonist triggering and intensive luteal steroidsupport on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study, " Journal of Ovarian Research, vol. 6, no. 1, article 93, 2013.
31. P. Humaidan, L. H. Thomsen, and B. Alsbjerg, "GnRHa trigger and modified luteal support with one bolus of hCG should be used with caution in extreme responder patients, " Human Reproduction, vol. 28, no. 9, pp. 2593-2594, 2013.
32. E. G. Papanikolaou, W. Verpoest, H. Fatemi, B. Tarlatzis, P. Devroey, and H. Tournaye, "A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study, " Fertility and Sterility, vol. 95, no. 3, pp. 1174-1177, 2011.
33. L. Engmann, A. DiLuigi, D. Schmidt, C. Benadiva, D. Maier, and J. Nulsen, "The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study, " Fertility and Sterility, vol. 89, no. 3, pp. 554-561, 2008.
34. B. S. Shapiro, S. T. Daneshmand, F. C. Garner, M. Aguirre, and C. Hudson, "Comparison of 'triggers' using leuprolide acetate alone or in combinationwith low-dose human chorionic gonadotropin, " Fertility and Sterility, vol. 95, no. 8, pp. 2715-2717, 2011.
35. R. Orvieto, "Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help?" Reproductive BioMedicine Online, vol. 24, no. 6, pp. 680-681, 2012.
36. J. Balasch, F. Martinez, I. Jove et al., "Inadvertent gonadotrophin-releasing hormone agonist (GnRHa) administration in the luteal phase may improve fecundity in in-vitro fertilization patients, " Human Reproduction, vol. 8, no. 7, pp. 1148-1151, 1993.
37. P. Humaidan, H. E. Bredkj'r, L. Bungum et al., "GnRH agonist (buserelin) or hCGfor ovulation induction inGnRH antagonist IVF/ICSI cycles: a prospective randomized study, " Human Reproduction, vol. 20, no. 5, pp. 1213-1220, 2005.
38. E. M. Kolibianakis, A. Schultze-Mosgau, A. Schroer et al., "A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists, " Human Reproduction, vol. 20, no. 10, pp. 2887-2892, 2005.
39. M. A. Youssef, F. Van der Veen, H. G. Al-Inany et al., "Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles, " Cochrane Database of Systematic Reviews, no. 11, Article ID CD008046, 2011.
40. B. Acevedo, J. L. Gomez-Palomares, E. Ricciarelli, and E. R. Hernández, "Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates, " Fertility and Sterility, vol. 86, no. 6, pp. 1682-1687, 2006.
41. G. Griesinger, E. M. Kolibianakis, E. G. Papanikolaou et al., "Triggering of final oocyte maturation with gonadotropinreleasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles, " Fertility and Sterility, vol. 88, no. 3, pp. 616-621, 2007.
42. E. M. Casañ, F. Raga, and M. L. Polan, "GnRH mRNA and protein expression in human preimplantation embryos, "Molecular Human Reproduction, vol. 5, no. 3, pp. 234-239, 1999.
43. E. M. Casañ, F. Raga, F. Bonilla-Musoles, and M. L. Polan, "Human oviductal gonadotropin-releasing hormone: possible implications in fertilization, early embryonic development, and implantation, " The Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 4, pp. 1377-1381, 2000.
44. F. Raga, E. M. Casañ, J. Kruesse, Y. Wen, F. Bonilla-Musoles, and M. L. Polan, "The role of gonadotropin-releasing hormone in murine preimplantation embryonic development, " Endocrinology, vol. 140, no. 8, pp. 3705-3712, 1999.
45. K. Kawamura, J. Fukuda, J. Kumagai et al., "Gonadotropinreleasing hormone I analog acts as an anti-apoptotic factor in mouse blastocysts, " Endocrinology, vol. 146, no. 9, pp. 4105-4116, 2005.
46. D. H. Nam, S. H. Lee, H. S. Kimet al., "Therole of gonadotropinreleasing hormone (GnRH) and its receptor in development of porcine preimplantation embryos derived from in vitro fertilization, "Theriogenology, vol. 63, no. 1, pp. 190-201, 2005.
47. L.-S. Lin, V. J. Roberts, and S. S. Yen, "Expression of human gonadotropin-releasing hormone receptor gene in the placenta and its functional relationship to human chorionic gonadotropin secretion, " Journal of Clinical Endocrinology and Metabolism, vol. 80, no. 2, pp. 580-585, 1995.
48. D. Islami, D. Chardonnens, A. Campana, and P. Bischof, "Comparison of the effects of GnRH-I and GnRH-II on HCG synthesis and secretion by first trimester trophoblast, "Molecular Human Reproduction, vol. 7, no. 1, pp. 3-9, 2001.
49. F. Raga, E. M. Casañ, J. S. Kruessel et al., "Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle, " Biology of Reproduction, vol. 59, no. 3, pp. 661-669, 1998.
50. M. Shemesh, "Actions of gonadotrophins on the uterus, " Reproduction, vol. 121, no. 6, pp. 835-842, 2001.
51. P. A. B. Klemmt, F. Liu, J. G. Carver et al., "Effects of gonadotrophin releasing hormone analogues on human endometrial stromal cells and embryo invasion in vitro, " Human Reproduction, vol. 24, no. 9, pp. 2187-2192, 2009.
52. J. B. A. Oliveira, R. Baruffi, C. G. Petersen, A. L. Mauri, M. Cavagna, and J. G. Franco Jr., "Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a metaanalysis, " Reproductive Biology and Endocrinology, vol. 8, article 107, 2010.
53. E. A. Stewart, "Gonadotropins and the uterus: is there a gonadindependent pathway?" Journal of the Society for Gynecologic Investigation, vol. 8, no. 6, pp. 319-326, 2001.
54. C. V. Rao and Z. M. Lei, "Consequences of targeted inactivation of LH receptors, "Molecular and Cellular Endocrinology, vol. 187, no. 1-2, pp. 57-67, 2002.
55. J. Tesarik, A. Hazout, and C. Mendoza, "Luteinizing hormone affects uterine receptivity independently of ovarian function, " Reproductive BioMedicine Online, vol. 7, no. 1, pp. 59-64, 2003.
56. E. Loumaye, S. Depreester, J. Donnez, and K. Thomas, "Immunoreactive relaxin surge in the peritoneal fluid ofwomen during themidluteal phase, " Fertility and Sterility, vol. 42, no. 6, pp. 856-860, 1984.
57. P. Licht, V. Russu, and L. Wildt, "On the role of human chorionic gonadotropin (hCG) in the embryo-endometrial microenvironment: Implications for differentiation and implantation, " Seminars in ReproductiveMedicine, vol. 19, no. 1, pp. 37-47, 2001.